Search Results - "Foltz, Ian N"

Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer’s disease by Ellwanger, Daniel C., Wang, Shoutang, Brioschi, Simone, Shao, Zhifei, Green, Lydia, Case, Ryan, Yoo, Daniel, Weishuhn, Dawn, Rathanaswami, Palaniswami, Bradley, Jodi, Rao, Sara, Cha, Diana, Luan, Peng, Sambashivan, Shilpa, Gilfillan, Susan, Hasson, Samuel A., Foltz, Ian N., van Lookeren Campagne, Menno, Colonna, Marco

“…Triggering receptor expressed on myeloid cells 2 (TREM2) sustains microglia response to brain injury stimuli including apoptotic cells, myelin damage, and…”
Get full text

Molecular basis for the loss-of-function effects of the Alzheimer's disease–associated R47H variant of the immune receptor TREM2 by Sudom, Athena, Talreja, Santosh, Danao, Jean, Bragg, Eric, Kegel, Rob, Min, Xiaoshan, Richardson, Jason, Zhang, Zhongqi, Sharkov, Nikolai, Marcora, Edoardo, Thibault, Steve, Bradley, Jodi, Wood, Steve, Lim, Ai-Ching, Chen, Hang, Wang, Songli, Foltz, Ian N., Sambashivan, Shilpa, Wang, Zhulun

“…Triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor expressed on the surface of microglia, macrophages, dendritic cells, and…”
Get full text

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity by Graves, Jonathan D., Kordich, Jennifer J., Huang, Tzu-Hsuan, Piasecki, Julia, Bush, Tammy L., Sullivan, Timothy, Foltz, Ian N., Chang, Wesley, Douangpanya, Heather, Dang, Thu, O’Neill, Jason W., Mallari, Rommel, Zhao, Xiaoning, Branstetter, Daniel G., Rossi, John M., Long, Alexander M., Huang, Xin, Holland, Pamela M.

“…Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not…”
Get full text

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody by Stewart, Ross, Morrow, Michelle, Hammond, Scott A, Mulgrew, Kathy, Marcus, Danielle, Poon, Edmund, Watkins, Amanda, Mullins, Stefanie, Chodorge, Matthieu, Andrews, John, Bannister, David, Dick, Emily, Crawford, Nicola, Parmentier, Julie, Alimzhanov, Marat, Babcook, John S, Foltz, Ian N, Buchanan, Andrew, Bedian, Vahe, Wilkinson, Robert W, McCourt, Matthew

“…Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation. Many tumors can upregulate expression of…”
Get more information

Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform by Foltz, Ian N., Gunasekaran, Kannan, King, Chadwick T.

“…Summary Since the late 1990s, the use of transgenic animal platforms has transformed the discovery of fully human therapeutic monoclonal antibodies. The first…”
Get full text

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma by Hamblett, Kevin J, Kozlosky, Carl J, Siu, Sophia, Chang, Wesley S, Liu, Hua, Foltz, Ian N, Trueblood, Esther S, Meininger, David, Arora, Taruna, Twomey, Brian, Vonderfecht, Steven L, Chen, Qing, Hill, John S, Fanslow, William C

“…Epidermal growth factor receptor variant III (EGFRvIII) is a cancer-specific deletion mutant observed in approximately 25% to 50% of glioblastoma multiforme…”
Get full text

TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function by Cheng, Qingwen, Danao, Jean, Talreja, Santosh, Wen, Paul, Yin, Jun, Sun, Ning, Li, Chi-Ming, Chui, Danny, Tran, David, Koirala, Samir, Chen, Hang, Foltz, Ian N., Wang, Songli, Sambashivan, Shilpa

“…Triggering receptor expressed on myeloid cells 2 (TREM2) is an orphan immune receptor expressed on cells of myeloid lineage such as macrophages and microglia…”
Get full text

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types by Kaplan-Lefko, Paula J., Graves, Jonathan D., Zoog, Stephen J., Pan, Yang, Wall, Jason, Branstetter, Daniel G., Moriguchi, Jodi, Coxon, Angela, Huard, Justin N., Xu, Ren, Peach, Matthew L., Juan, Gloria, Kaufman, Stephen, Chen, Qing, Bianchi, Allison, Kordich, Jennifer J., Ma, Mark, Foltz, Ian N., Gliniak, Brian C.

“…Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors 4 and 5 (DR4, DR5) to transduce apoptotic signals.  Conatumumab (AMG…”
Get full text

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo by Jenkins, David W, Ross, Sarah, Veldman-Jones, Margaret, Foltz, Ian N, Clavette, Brandon C, Manchulenko, Kathy, Eberlein, Cath, Kendrew, Jane, Petteruti, Philip, Cho, Song, Damschroder, Melissa, Peng, Li, Baker, Dawn, Smith, Neil R, Weir, Hazel M, Blakey, David C, Bedian, Vahe, Barry, Simon T

“…The Notch signaling pathway has been implicated in cell fate determination and differentiation in many tissues. Accumulating evidence points toward a pivotal…”
Get full text

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product by Seo, Neungseon, Guan, Xiaoyan, Wang, Tian, Chung, Hyo S. Helen, Wikström, Mats, Padaki, Rupa, Kalenian, Kevin, Kuhns, Scott, Matthies, Kelli, Crouse-Zeineddini, Jill, Wong, Helen Y., Ng, Michael, Foltz, Ian N., Cao, Shawn, Liu, Jennifer

“…Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders…”
Get full text

Evolution and Emergence of Therapeutic Monoclonal Antibodies: What Cardiologists Need to Know by FOLTZ, Ian N, KAROW, Margaret, WASSERMAN, Scott M

Get full text

Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG by Gunasekaran, Kannan, Pentony, Martin, Shen, Min, Garrett, Logan, Forte, Carla, Woodward, Anne, Ng, Soo Bin, Born, Teresa, Retter, Marc, Manchulenko, Kathy, Sweet, Heather, Foltz, Ian N, Wittekind, Michael, Yan, Wei

“…Naturally occurring IgG antibodies are bivalent and monospecific. Bispecific antibodies having binding specificities for two different antigens can be produced…”
Get full text

Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence–based affinity maturation by Kielczewska, Agnieszka, D'Angelo, Igor, Amador, Maria Sheena, Wang, Tina, Sudom, Athena, Min, Xiaoshan, Rathanaswami, Palaniswami, Pigott, Craig, Foltz, Ian N.

“…Therapeutic antibody development requires discovery of an antibody molecule with desired specificities and drug-like properties. For toxicological studies, a…”
Get full text

Native SEC and Reversed-Phase LC–MS Reveal Impact of Fab Glycosylation of Anti-SARS-COV‑2 Antibodies on Binding to the Receptor Binding Domain by Woodall, Daniel W., Thomson, Christy A., Dillon, Thomas M., McAuley, Arnold, Green, Lydia B., Foltz, Ian N., Bondarenko, Pavel V.

“…The binding affinity of monoclonal antibodies (mAbs) for their intended therapeutic targets is often affected by chemical and post-translational modifications…”
Get full text

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex by Foltz, Ian N, Hu, Sylvia, King, Chadwick, Wu, Xinle, Yang, Chaofeng, Wang, Wei, Weiszmann, Jennifer, Stevens, Jennitte, Chen, Jiyun Sunny, Nuanmanee, Noi, Gupte, Jamila, Komorowski, Renee, Sekirov, Laura, Hager, Todd, Arora, Taruna, Ge, Hongfei, Baribault, Helene, Wang, Fen, Sheng, Jackie, Karow, Margaret, Wang, Minghan, Luo, Yongde, McKeehan, Wallace, Wang, Zhulun, Véniant, Murielle M, Li, Yang

“…Fibroblast growth factor 21 (FGF21) is a distinctive member of the FGF family with potent beneficial effects on lipid, body weight, and glucose metabolism and…”
Get more information

A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism by Liu, Zhi, Leng, Esther C., Gunasekaran, Kannan, Pentony, Martin, Shen, Min, Howard, Monique, Stoops, Janelle, Manchulenko, Kathy, Razinkov, Vladimir, Liu, Hua, Fanslow, William, Hu, Zhonghua, Sun, Nancy, Hasegawa, Haruki, Clark, Rutilio, Foltz, Ian N., Yan, Wei

“…Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for preclinical and clinical testing is a challenging task. Here, we describe a…”
Get full text

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab by Jassem, Shea, Wang, Wei, Sweet, Heather, Manoukian, Raffi, Chow, Vincent, Kanakaraj, Palanisamy, Hutterer, Katariina M., Kuhns, Scott, Foltz, Ian N., Chen, Qing, Ferbas, John, McBride, Helen J.

“…Purpose The in vitro and in vivo pharmacologic assessment of ABP 980 similarity to its reference product is intended to compare the activity of ABP 980 and…”
Get full text

The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering by Walker, Kenneth W., Foltz, Ian N., Wang, Tina, Salimi-Moosavi, Hossein, Bailis, Julie M., Lee, Fei, An, Phillip, Smith, Stephen, Bruno, Richele, Wang, Zhulun

“…Transthyretin (TTR) is an abundant homotetrameric serum protein and was selected here for engineering higher-valency molecules because of its compact size,…”
Get full text

Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies by Grujic, Ognjen, Stevens, Jennitte, Chou, Robert Y.-T., Weiszmann, Jennifer V., Sekirov, Laura, Thomson, Christy, Badh, Anita, Grauer, Stephanie, Chan, Brian, Graham, Kevin, Manchulenko, Kathy, Dillon, Thomas M., Li, Yang, Foltz, Ian N.

“…Agonism of cell surface receptors by monoclonal antibodies is dependent not only on its ability to bind the target, but also to deliver a biological signal…”
Get full text

Kinetic analysis of unpurified native antigens available in very low quantities and concentrations by Rathanaswami, Palaniswami, Richmond, Karen, Manchulenko, Kathy, Foltz, Ian N.

“…Affinity measurements of antigen–antibody interactions are generally performed using known concentrations of purified or recombinant materials. In addition,…”
Get full text